Baclofen/gabapentin

  • PDF / 169,677 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 59 Downloads / 198 Views

DOWNLOAD

REPORT


1 S

Acute kidney injury: case report A 39-year-old woman developed acute kidney injury during treatment with gabapentin and baclofen for pain management. The woman, who had a history of cervical cancer and cisplatin-induced chronic kidney disease, underwent intrathecal infusion pump placement for pain management. She was also commenced on oral baclofen and oral gabapentin [dosage not stated]. Eleven weeks later, she was hospitalised for management of elevated creatinine, thrombocytopenia and anaemia. On day 4 of hospital admission, she became somnolent, but denied headaches, neck stiffness and had normal vitals. A non-contrasted head CT revealed no evidence of hydrocephalus or haemorrhage, but fat globules were dispersed throughout the subarachnoid space. There was no subarachnoid fat on head CT five months prior to the admission. She returned to her baseline mental status the next day. She was diagnosed with intrathecal infusion pump-related deposition of the fat globules in to the subarachnoid space. Additionally, her elevated creatinine level was attributed to acute kidney injury caused by gabapentin and baclofen. The woman’s baclofen and gabapentin dosages were reduced due to acute kidney injury [outcome not stated]. Brain and full spine MRI re-demonstrated subarachnoid fat globules, without evidence of an underlying dermoid tumour. She was discharged and had no further neurologic sequelae. A repeat head CT 7 weeks later showed stable subarachnoid fat burden. Riestenberg RA, et al. Subarachnoid fat dissemination secondary to intrathecal pump. Journal of Clinical Neuroscience 78: 416-417, Aug 2020. Available from: URL: http:// 803500872 doi.org/10.1016/j.jocn.2020.04.120

0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Sep 2020 No. 1821

Data Loading...